Tumor and infectious disease therapeutic compositions

Abstract

A pharmaceutical composition comprising lectins is anti-tumorigenic and anti-viral, bacterial or protozoan. The composition, termed BiOmune is also useful for imaging, diagnosis and therapy of cancer.

1 . A pharmaceutical composition comprising: 
 lectin;    immunogenicity modifier;    pokeweed mitogen; and,    polyetheylene glycol.    
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the lectin is coupled to an immunogenicity modifier.  
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the immunogenicity modifier is a hapten.  
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein the hapten is 2,4-dinitrophenol (DNP).  
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the pokeweed mitogen is coated with polyethylene glycol.  
     
     
         6 . The pharmaceutical composition of  claim 1 , which further comprises interleukin molecules.  
     
     
         7 . The pharmaceutical composition of  claim 6 , wherein the interleukin molecules are Interleukin-2.  
     
     
         8 . The pharmaceutical composition of  claim 1 , wherein the lectin is selected from the group consisting of  Anguilla anguilla  (Eel serum);  Aleuria aurantia  (Orange peel fungus);  Agaricus bisporus  (Mushroom);  Amphicarpanea bracteata  (hog-peanut);  Hippaestrum hybrid  (Amaryllis bulbs);  Abrus precatorius  (Jequirity bean);  Bauhinia purpurea alba  (camel's foot tree);  Caragana arborescens  (Siberian pea tree);  Concanavalia ensiformis  (Jack bean);  Cicer arietinum  (chick pea);  Cytisus scoparius  (Scotch broom);  Colichos biflorus  (horse gram);  Datura stramonium  (Jimson weed, Thorn apple);  Erythrina crystagalli  (Coral tree);  Erythrina coralldendron  (Coral tree);  Euonymus europaeus  (spindle tree);  Dolichos biflorus  (horse gram);  Galanthus nivalis  (Snowdrop bulb);  Griffonia simplicifolia; Helix aspersa  (Garden snail);  helix pomatia; Artocarpus integrifolia  (jackfruit);  Laburnum alpinum; Phaseolus lunatis  (also limensis) (Lima bean);  Lens culinaris  (lentil);  Lycopersicon esculentum  (Tomato);  Lathyrus oderatus  (Sweet pea);  Lotus tetragonolobus  (Asparagus pea);  Maackla amurensis  ( maackla );  Maclura pomifera  (Osage orange);  Narcissus pseudonarcissus  (daffodil);  Phytolacca americana  (Pokeweed);  Phaseolis vulgaris  (Red kidney bean);  Arachis hypogaea  (Peanut);  Pisum sativum  (Pea);  Phytolacca americana  (pokeweed);  Psophocarpus tetagonolobus  (winged bean);  Psophocarpus tetagonolobus  (winged bean);  Ricinus communis  (Castor bean);  Robinia pseudoaccacia  (black locust);  Glycine max  (Soybean);  Sophora japonica  (Japanese pagoda tree);  Solanum tuberosum  (Potato);  Trichosanthes kinlowii  (China gourd);  Ulex europaeus  (Gorse or Furz seeds);  Viscum album  (European mistletoe);  Vicia faba  (Fava bean);  Vicia graminea; Vigna radiata  (mung bean);  Vicia sativa; Vicia villosa  (Hairy vetch);  Wisteria floribunda  (Japanese wisteria);  Triticum vulgaris  (Wheat germ); and suc-WGA (Succinyl WGA).  
     
     
         9 . The pharmaceutical composition of  claim 8 , wherein the lectin is Helix pomatia.  
     
     
         10 . A pharmaceutical composition comprising a nucleotide molecule as identified by SEQ ID NO: 1, derivatives, variants and fragments thereof.  
     
     
         11 . The pharmaceutical composition of  claim 10 , wherein the nucleotide molecule is admixed with 1,2 dioleoyl-3-trimethylammonium-propane and cholesterol.  
     
     
         12 . A pharmaceutical composition comprising: 
 lectin;    immunogenicity modifier;    pokeweed mitogen;    polyetheylene glycol; and,    a nucleic acid molecule.    
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein the lectin is coupled to an immunogenicity modifier.  
     
     
         14 . The pharmaceutical composition of  claim 12 , wherein the immunogenicity modifier is a hapten.  
     
     
         15 . The pharmaceutical composition of  claim 14 , wherein the hapten is 2,4-dinitrophenol (DNP).  
     
     
         16 . The pharmaceutical composition of  claim 12 , wherein the pokeweed mitogen is coated with polyethylene glycol.  
     
     
         17 . The pharmaceutical composition of  claim 12 , which further comprises interleukin molecules.  
     
     
         18 . The pharmaceutical composition of  claim 17 , wherein the interleukin molecules are Interleukin-2.  
     
     
         19 . The pharmaceutical composition of  claim 12 , wherein the lectin is selected from the group consisting of  Anguilla anguilla  (Eel serum);  Aleuria aurantia  (Orange peel fungus);  Agaricus bisporus  (Mushroom);  Amphicarpanea bracteata  (hog-peanut);  Hippaestrum hybrid  (Amaryllis bulbs);  Abrus precatorius  (Jequirity bean);  Bauhinia purpurea alba  (camel's foot tree);  Caragana arborescens  (Siberian pea tree);  Concanavalia ensiformis  (Jack bean);  Cicer arietinum  (chick pea);  Cytisus scoparius  (Scotch broom);  Colichos biflorus  (horse gram);  Datura stramonium  (Jimson weed, Thorn apple);  Erythrina crystagalli  (Coral tree);  Erythrina coralldendron  (Coral tree);  Euonymus europaeus  (spindle tree);  Dolichos biflorus  (horse gram);  Galanthus nivalis  (Snowdrop bulb);  Griffonia simplicifolia; Helix aspersa  (Garden snail);  helix pomatia; Artocarpus integrifolia  (jackfruit);  Laburnum alpinum; Phaseolus lunatis  (also limensis) (Lima bean);  Lens culinaris  (lentil);  Lycopersicon esculentum  (Tomato);  Lathyrus oderatus  (Sweet pea);  Lotus tetragonolobus  (Asparagus pea);  Maackla amurensis  ( maackla );  Maclura pomifera  (Osage orange);  Narcissus pseudonarcissus  (daffodil);  Phytolacca americana  (Pokeweed);  Phaseolis vulgaris  (Red kidney bean);  Arachis hypogaea  (Peanut);  Pisum sativum  (Pea);  Phytolacca americana  (pokeweed);  Psophocarpus tetagonolobus  (winged bean);  Psophocarpus tetagonolobus  (winged bean);  Ricinus communis  (Castor bean);  Robinia pseudoaccacia  (black locust);  Glycine max  (Soybean);  Sophora japonica  (Japanese pagoda tree);  Solanum tuberosum  (Potato);  Trichosanthes kinlowii  (China gourd);  Ulex europaeus  (Gorse or Furz seeds);  Viscum album  (European mistletoe);  Vicia faba  (Fava bean);  Vicia graminea; Vigna radiata  (mung bean);  Vicia sativa; Vicia villosa  (Hairy vetch);  Wisteria floribunda  (Japanese wisteria);  Triticum vulgaris  (Wheat germ); and suc-WGA (Succinyl WGA).  
     
     
         20 . The pharmaceutical composition of  claim 12 , wherein the lectin is Helix pomatia.  
     
     
         21 . The pharmaceutical composition of  claim 12 , wherein the nucleic acid molecule is identified by SEQ ID NO: 1  
     
     
         22 . The pharmaceutical composition of  claim 21 , wherein the nucleic acid molecule is SEQ ID NO: 1, derivatives, variants and fragments thereof.  
     
     
         23 . The pharmaceutical composition of  claim 12 , wherein the nucleic acid molecule is admixed with 1,2 dioleoyl-3-trimethylammonium-propane and cholesterol.  
     
     
         24 . The pharmaceutical composition of  claim 12 , wherein the nucleic acid molecule is Poly (I:C).  
     
     
         25 . A method of treating a cancer patient, comprising; 
 administering to a patient in need thereof, a composition as in any one of claims  1  or  12 ;    contacting a tumor cell with the composition resulting in the lysis of the tumor cell;    thereby treating the cancer patient.    
     
     
         26 . A method of inhibiting immunoglobulin isoclass switching in a cancer patient and/or patient suffering from an infectious disease organism, comprising: 
 administering to a patient in need thereof, a composition as in any one of claims  1  or  12 ;    contacting a tumor cell and/or infected cell with the composition resulting in the lysis of the cells;    thereby treating the patient.    
     
     
         27 . The method of  claim 26 , wherein immunoglobulin M (IgM) is inhibited from switching to immunoglobulin G (IgG).  
     
     
         28 . The method of  claim 27 , wherein the IgM fixes complement on a tumor and/or infected cell.